Where I see patients (1)
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meni...
Percentage of patients who are progression-free at the landmark of 12 months from start of treatment based on the target lesion(s) that are receiving radiation treatment will be reported. Tumor progression will be assessed using I...
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Tumor to plasma partition coefficients of niraparib for total (Kp) and unbound (Kp,uu) drug levels